| Saillant Therapeutics BV is an innovative biotechnology company that develops promising small molecule-based therapies against heart failure. The aim of this trajectory is to demonstrate preclinical proof-of-concept for one or two drug candidates and market access preparation to enable clinical validation of a novel drug candidate for heart failure. The drug candidate(s) will be a first-in-kind drug therapy for heart failure patients by targeting a unique mechanism of action. Heart failure is a life-threatening disease that affects 26 million patients around the globe. |
